Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25391410 | 0.94 | NPSR1 (0.36) | NPSR1CYP1A2CYP2C9CYP2C19KDM4E | |
| Hydrochloric Acid SCHEMBL18038823 | 0.91 | NPSR1 (0.34) | NPSR1KDM4EALDH1A1NPC1GAA | |
| SCHEMBL15266297 | 0.79 | CCNB2 (0.31) | — | |
| SCHEMBL2962859 | 0.76 | CYP1A2 (0.39) | NPSR1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL31308733 | 0.75 | — | — | |
| SCHEMBL18038824 | 0.74 | CYP1A2 (0.40) | NPSR1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL30606887 | 0.74 | CYP1A2 (0.40) | NPSR1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL18038754 | 0.71 | KDM5B (0.41) | CYP1A2CYP2C9CYP2C19ALDH1A1HPGD | |
| SCHEMBL31591386 | 0.69 | ALDH1A1 (0.35) | ALDH1A1GLARAB9A | |
| SCHEMBL31591369 | 0.68 | GPR119 (0.32) | ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-107531668-B | Therapeutic pyridazine compounds and uses thereof | 基因泰克公司 | 2021-10-29 | — | — | CN | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| EP-3262036-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138114-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | NPSR1 3059/4885CYP1A2 4326/4885CYP2C9 4614/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | NPSR1 3059/4885CYP1A2 4326/4885CYP2C9 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.